New drug cocktail tested for Tough-to-Treat penile cancer
NCT ID NCT07384416
Summary
This study is testing a new combination of three drugs (QL1706, lenvatinib, and nab-paclitaxel) for men with advanced penile cancer that has come back or stopped responding to other treatments. The main goals are to see if this combination can shrink tumors or delay cancer growth, and to understand what side effects patients experience. All participants will receive the same three-drug treatment, which includes two drugs given by IV every three weeks and one daily pill.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PENILE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.